[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:acute-relapsing-multiple-sclerosis":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":28,"states":29},"Acute relapsing multiple sclerosis",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07609719","A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy",[11],"Phase 4","RECRUITING","2026-08-03T02:41:09.847474Z","2026-05-29T15:36:40.228777Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06846281","Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.",[19],"Phase 3","2026-08-26T02:18:29.369233Z","2026-05-05T02:43:28.811370Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT06433752","A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)",[],"2026-08-26T02:17:27.435233Z","2026-05-13T02:55:06.492326Z",[],[30,33,36,39,42],{"state":31,"count":5,"slug":32},"Arizona","arizona",{"state":34,"count":5,"slug":35},"Florida","florida",{"state":37,"count":5,"slug":38},"Ohio","ohio",{"state":40,"count":5,"slug":41},"Tennessee","tennessee",{"state":43,"count":5,"slug":44},"Texas","texas"]